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Introduction
Almost all patients treated in adult general intensive 
care units (ICUs) carry an increased risk for acute kid-
ney injury (AKI). This syndrome of abruptly decreased 
glomerular filtration rate was diagnosed in over 50% of 
critically ill patients in a multinational cohort study and 
is associated with a variety of adverse short-term [1] and 
long-term outcomes [2, 3]. Therefore, being aware of 
AKI and staying up-to-date regarding the implications 
of latest clinical research are relevant to all intensivists. 
This issue of Intensive Care Medicine provides a com-
prehensive collection of the latest advances in the field 
of AKI research as well as expert opinions and reviews 
covering topics about AKI in specific populations [4, 5] 
as well as key elements of AKI management [6, 7]. This 
set of papers combines state-of-the-art knowledge and 
new ideas to improve current clinical practice and rep-
resents “required reading” for practicing intensivists with 
all major aspects of this syndrome being analyzed and 
reviewed in depth.
The unified definition of AKI [8], although not with-
out challenges [9], has resulted in better understanding 
of epidemiology and promoted standardization of trial 
endpoints [10]. Moreover, significant effort has been 
invested in the search for predictive biomarkers of AKI. 
Although initial results were disappointing [11], failures 
in the biomarker field have increased our understanding 
of this syndrome and, more recently, cell cycle arrest bio-
markers seem to hold greater promise for better patient 
care [12]. At the same time, animal research has revealed 
the potentially different pathophysiology behind septic 
AKI. Such understanding may allow advances in drug 
development and some promising agents are currently 
being tested in septic AKI [4].
Adequate identification of patients with an increased 
risk for AKI is a key element in the chain of prevention of 
AKI. Flechet et al. report encouraging results from their 
analysis in the EPaNIC database showing that models 
comprising routinely collected data outperformed neu-
trophil gelatinase-associated lipocalin in predicting AKI 
[13]. Furthermore, a challenge for any predictive tool is to 
improve care. Meersch et al. have recently used cell cycle 
arrest biomarkers in cardiac surgical patients to define 
subjects with high risk and randomized them either to a 
treatment bundle aiming at avoiding further nephrotoxic 
insults and optimization of the hemodynamic status or 
to standard care. This approach resulted in a lower rate 
of developing AKI, but the study was underpowered to 
examine renal recovery or mortality rates [12]. This sin-
gle-center trial turns a new page in biomarker research to 
biomarker-directed management protocols for AKI pre-
vention and treatment and should hopefully prompt oth-
ers to study interventions using enrichment strategies.
Management of AKI
Fluid therapy is administered to all ICU patients. Patients 
with oliguric AKI are at especially high risk of develop-
ing fluid overload that associates with increased mortal-
ity. Therefore, understanding when additional fluids can 
be beneficial in oliguria and when they can cause harm is 
a key element in the management of these patients [14]. 
Strategies that deliver more fluids are clearly not superior 
to strategies that deliver less fluid either for prevention or 
resolution of AKI in the setting of septic shock. In addi-
tion, knowledge of different fluid types and their poten-
tial harm has greatly increased, and the review by Perner 
et  al. provides comprehensive insights into these issues 
[7].
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About one-fifth of patients with AKI commence renal 
replacement therapy (RRT) [1]. The optimal time to start 
RRT in the absence of emergency indications remains 
uncertain, but the STARRT-AKI trial (NCT02568722) is 
now well underway and is likely to bring high-level evi-
dence to the field along with other recent trials that are 
discussed in the review summarizing the state-of-the-art 
for management of RRT by Bagshaw et al. [6]. The issue 
of optimal timing for the discontinuation of RRT also 
lacks definitive evidence, but Forni et al. provide practi-
cal insights into the topic in their viewpoint on this issue. 
Moreover, in future we may be able to provide continu-
ous RRT that uses dynamic biofeedback loops from data 
regarding fluid balance and blood chemistry to provide 
an optimal dialysis dose [15].
Follow‑up
Adverse consequences of AKI on long-term renal func-
tion are becoming increasingly known, although studies 
prospectively assessing renal function of AKI survivors 
are few. The recovery process from AKI can be fluctuat-
ing with different scenarios. Even after initial recovery, 
patients remain at increased risk of developing chronic 
kidney disease. Therefore, all patients exposed to RRT 
may benefit from nephrologist follow-up to address 
treatable and avoidable risk factors and to minimize 
potential further worsening of renal function [2, 3].
Clinical trials
Despite doubling of AKI-related citations during the 
last 10 years, many key areas still lack good-quality evi-
dence and treatment recommendations are often based 
on expert opinions [16]. However, active research has 
challenged many long-standing beliefs and provided evi-
dence-based guidance in key areas such as, for example, 
the dose of RRT [6, 17]. Issues such as AKI care bundles, 
RRT discontinuation, fluid restriction and removal, novel 
pathophysiology-based pharmacological interventions, 
recruitment of renal functional reserve [18], and use of 
chloride-rich fluids in heterogeneous ICU populations 
are among the proposed top ten trials to be conducted 
within the next 10 years [17]. Hopefully, these and other 
trials will bring advances in the field of AKI management 
that can be translated into improvements in patient-cen-
tered outcomes worldwide.
Conclusions
Our knowledge about how to diagnose, prevent, and treat 
AKI has rapidly evolved during the last decade. Figure 1 
summarizes current and potentially emerging means to 
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Fig. 1 Means of improving care of patients with acute kidney injury. AKI acute kidney injury, RRT renal replacement therapy
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improve patient care in this field. Hopes are high for the 
development of more accurate and practical methods to 
measure deteriorating renal function thus allowing ear-
lier diagnosis and enabling frequent and more accurate 
monitoring. Earlier diagnosis would allow prevention 
of further deterioration, especially if pharmacotherapy 
to prevent and treat AKI becomes available. However, 
before these potential interventions become available for 
daily clinical practice, all clinicians can still do their best 
to detect AKI, establish its etiology, avoid further renal 
insults, optimize fluid therapy and hemodynamics, pro-
vide high-quality RRT, and make sure that information 
about the AKI episode is conveyed to colleagues taking 
care of the patient after ICU discharge. The well-being 
of AKI patients depends on such awareness, knowledge, 
clinical skills, and diligence. Our patients deserve no less.
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